This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Valeant Pharmaceuticals(VRX) said Monday that it will pay $8.7 billion to buy
Bausch & Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of Valeant's smaller ophthalmology business.
Valeant said the cash deal will help it capitalize on increasing demand for contact lenses and other products because of aging populations, growing demand in emerging markets and increasing rates of diabetes. Complications of the complex blood sugar disorder can damage the eyes over time.
Investment firm Warburg Pincus, which leads an investment group that owns Bausch & Lomb, will receive $4.5 billion in cash. The remaining $4.2 billion will be used to repay Bausch & Lomb's debt.
Reports that the purchase was in the works surfaced late last week.
The deal, which requires approval from regulators and other standard closing conditions, is expected to be completed in the third quarter. It will be financed with debt and about $1.5 billion to $2 billion in new stock.
Valeant expects to achieve at least $800 million in annual cost savings by the end of next year.
Rochester, N.Y.-based Bausch & Lomb Holdings Inc. makes contact lenses, eye drugs and ophthalmic surgical devices. It will keep its name and become a division of Valeant Pharmaceuticals International Inc., which is based in Laval, Quebec.
"I am confident that under their stewardship, the Bausch & Lomb brand will continue to stand for excellence and innovation in eye health," Brent Saunders, CEO of Bausch & Lomb, said in a statement.
"Bausch & Lomb has undergone a profound transformation over the last few years," Saunders said. "We introduced innovative new products for patients, built a robust pipeline, expanded into new markets and strengthened our relationships with eye care professionals around the world."
Valeant's ophthalmology business will be folded into the new Bausch & Lomb division. The combined global business would have 2013 revenue topping $3.5 billion on a pro forma basis, meaning the total of sales from both companies' eye care businesses for the full year.
Much of that will come from Bausch & Lomb, which anticipates it will have revenue of about $3.3 billion this year. Bausch & Lomb expects adjusted earnings before interest, taxes, depreciation and amortization of about $720 million.